Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Friday.

In morning trade, the ASX All Ords stock is up 7% to $1.51.

A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

Why is this ASX All Ords stock jumping today?

Investors have been buying the regenerative medicine company's shares following the release of an announcement relating to its flagship Remplir product.

Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.

It was recently given the thumbs up by the US Food & Drug Administration, paving the way for the company to start generating revenue in the country.

Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US$3.5 billion.

What is today's news?

According to the release, the company has added a further eight distributors for Remplir, taking the total number of US distributors signed to 12.

Management notes that the signing of distributors has progressed well ahead of expectations with the company previously only targeting 10 distributors in place by 30 June. It feels that the rapid signing of these new distributors is a testament to the quality of Remplir and the distributors' belief in being able to generate strong sales for the product in the US.

Following these new appointments, the ASX All Ords stock's distributor group collectively covers 21 US states. And with these relationships non-exclusive, the company intends to continue signing additional distributors to expand access to the US market.

'Confident'

Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:

It's very pleasing to see such rapid progress on the expansion of our US distributor network so soon after receiving US FDA clearance in April. We're well ahead of the targets we had set ourselves and expect that to translate to first US Remplir sales this quarter.

Our US team has been working tirelessly leading up to the product launch and we're confident we have the right strategy to drive market penetration of the US. For us, that means a combination of experienced internal employees complemented by a portfolio of distributors who have active sales channels to reach and engage our customers. We expect to grow our portfolio of distributors too.

Following today's strong gain, this ASX All Ords stock is now up almost 300% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

Special dividend: Is now the time to buy NIB shares for income?

NIB shares now offer a yield well over 4%.

Read more »

Three healthcare workers standing together and smiling.
Healthcare Shares

Regis Healthcare reports higher FY26 profits and dividend

Regis Healthcare delivered higher revenue, profit and dividends in FY26, with occupancy and acquisitions driving strong results.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Could CSL shares really hit $200? Experts reveal their 12-month targets

Brokers warn CSL’s spectacular rebound doesn’t guarantee further gains.

Read more »

Five healthcare workers standing together and smiling.
ASX Share Market News

ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

Healthcare outperformed while the ASX 200 weakened as earnings season continued last week.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Telix shares are tumbling. Is the stock finally at fair value?

Telix's sell-off reflects valuation, competition, and heightened growth expectations.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why I'd buy Medibank shares for the dividend yield

Medibank is providing investors with very healthy dividends.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Fisher & Paykel Healthcare shares: Earnings outlook upgraded for FY27

Here's what the company expects to report for FY 2027.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Why I'd buy CSL, Cochlear, and Pro Medicus shares

These are three ASX healthcare shares I would be happy to own for years.

Read more »